| Summary: | Anticoagulant therapy (heparin or fondaparinux) is applied to prevent the the
extendibility of the thrombus and to avoid death in acute coronary syndrome
(ACS). From other research fondaparinux has better efficacy and more safety than
heparin. Heparin is the one of a narrow drug therapeutic level, it has more side
effect that can improve morbidity and decreasing their quality of life. The therapy
approach is not only focused on clinical outcomes but also the quality of life. This
research aims to find out the differences of the quality of life in ACS patients
treated with heparin and fondaparinux.
This research is a cohort study done in DR. Sardjito Hospital (Yogyakarta).
The sampling is consecutively done to the ACS patient with age between 35-80
years old who got heparin or fondaparinux therapy. MacNew questionnaire is
applied in this research. The data used in the research is a baseline and observation
done 1 month after therapy. Data that was analyzed was the changes of the score of
quality of life.
This research analyzed 54 patients of ACS, 3 people were dropout because
2 people death in the heparin groups and 1 people had changed the anticoagulant
therapy. There are 24 on fondaparinux group and 27 on heparin group, both groups
are dominated by male patients with risk factors of smoking, diabetes,
hypertension, and patients with STEMI. Change the average score of the quality of
life of the heparin about 1,4 ±0,22, meanwhile fondaparinux group about 1,7
±0,33. Significant difference is found between two groups (p = 0,000). The
patients with STEMI on fondaparinux group (1,8 ± 0,38) has better score quality of
life than heparin group (1,4 ± 0,15) with the significantly level about p=0,003.
The conclusion of this research is there are differences of quality of life to
fondaparinux and heparin group. The quality of life on fondaparinux group is
better than heparin group.
|
|---|